Compare Globus Medical Inc. Class A Common Stock (GMED) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Lockheed Martin Corporation — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.85 (market cap $10.25B), while Lockheed Martin Corporation trades at $527.89 (market cap $120.53B). The key difference: Lockheed Martin Corporation is far larger — about 11.8× Globus Medical Inc. Class A Common Stock's market cap, and Lockheed Martin Corporation pays a 2.76% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Lockheed Martin Corporation for 86 Days on average.
| GMED | LMT | |
|---|---|---|
Market Cap | $10.25B | $120.53B |
Volume | 1,059,528 | 1,477,073 |
Sector | Health | Industrials |
52-Week High | $96.82 | $676.70 |
52-Week Low | $58.33 | $439.19 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $9.76B | $137.27B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Lockheed Martin (LMT) trades at $504.02, down 1.54% on the day, with a bearish technical signal despite strong analyst support. The company reported mixed quarterly earnings with two misses and one beat, while maintaining robust cash flow generation and a 23-year dividend growth streak. Recent news highlights strategic AI partnerships and F-35 program developments.
LMT offers attractive valuation metrics with a P/E of 18.58 and strong analyst consensus pointing to 24% upside to the $625.64 price target. However, execution risks on fixed-price contracts and recent earnings volatility warrant caution despite the company's dominant defense contracting position and stable government funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
